Abstract
ObjectivesPersistently impaired culprit artery flow (<TIMI 3) during primary percutaneous coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects of intracoronary alteplase according to TIMI flow...
Highlights
Despite routinely restoring epicardial coronary patency with primary percutaneous138 coronary intervention (PCI), microvascular obstruction (MVO) affects about half of139 patients[1] and confers an adverse prognosis[2, 3]
Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published
78 Results: Thrombolysis in Myocardial Infarction (TIMI) flow was assessed after first treatment
Summary
Despite routinely restoring epicardial coronary patency with primary percutaneous138 coronary intervention (PCI), microvascular obstruction (MVO) affects about half of139 patients[1] and confers an adverse prognosis[2, 3]. 138 coronary intervention (PCI), microvascular obstruction (MVO) affects about half of. A key component of MVO is distal. 14 embolization and microvascular thrombi[4,5,6]. In the T-TIME trial (NCT02257294), we hypothesised that low-dose intracoronary. 142 alteplase, administered shortly after balloon angioplasty or aspiration thrombectomy, before. 143 stenting, would reduce intracoronary and microvascular thrombosis, and distal embolization, 24 thereby reducing MVO. 145 resonance (CMR), MVO did not differ with intracoronary alteplase vs placebo[7]. 31 onset, had a dose dependent increase in mean amount of MVO and myocardial haemorrhage. 148 with alteplase vs placebo[8]. Measured index of microcirculatory resistance did 149 not differ with intracoronary alteplase vs placebo[9], and there was no difference in clinical.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have